Evidence map›Paper›PMID 40131516›Full record

Trial reportEuropean journal of nutrition2025

Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial.

Evgeny Pokushalov, A Ponomarenko, C Garcia, L Kasimova, I Pak, E Shrainer, A Romanova, D Kudlay, M Johnson, R Miller

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06328348 (Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06328348 nacompletednot on this map

Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

TypeinterventionalSponsorS.LAB (SOLOWAYS)Ran2023 to 2023Enrolled96ConditionsMenopause SymptomsArmssupplementation, placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evgeny PokushalovCenter for New Medical Technologies, Novosibirsk, Russia. E.pokushalov@gmail.com.ORCID http://orcid.org/0000-0002-9494-4234
A PonomarenkoCenter for New Medical Technologies, Novosibirsk, Russia.
C GarciaScientific Research Laboratory, Triangel Scientific, San Francisco, USA.
L KasimovaCenter for New Medical Technologies, Novosibirsk, Russia.
I PakCenter for New Medical Technologies, Novosibirsk, Russia.
E ShrainerCenter for New Medical Technologies, Novosibirsk, Russia.
A RomanovaCenter for New Medical Technologies, Novosibirsk, Russia.
D KudlayCenter for New Medical Technologies, Novosibirsk, Russia.
M JohnsonScientific Research Laboratory, Triangel Scientific, San Francisco, USA.
R MillerScientific Research Laboratory, Triangel Scientific, San Francisco, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis randomized, double-blind, parallel-group clinical trial aimed to evaluate the efficacy of Black Cohosh, Soy Isoflavones, and SDG Lignans in alleviating menopausal symptoms compared to a placebo.

methodsNinety-six postmenopausal women aged 45-60 years were enrolled. Participants were randomized to receive either the study supplements or a placebo for 90 days, with Menopause Rating Scale (MRS) scores collected at baseline and every 4 weeks to monitor symptom changes. Secondary outcomes assessed included hormonal variations and the incidence of adverse symptoms.

resultsOf the initial cohort, 90 participants completed the study with high adherence. Significant improvements were observed in the treatment group across all MRS domains: somatic (- 54.3% difference, p < 0.01), psychological (- 54.3% difference, p < 0.01), urogenital (-37.3% difference, p < 0.01), and total score (- 48.0% difference, p < 0.01). Hormonal changes were modest yet statistically significant for FSH (- 6.7% difference, p < 0.01) and estradiol (12.6% difference, p < 0.01). Adverse events were minimal, transient, and did not require cessation of supplementation.

conclusionBlack Cohosh, Soy Isoflavones, and SDG Lignans significantly reduced menopausal symptoms with a favorable safety profile. These findings support the potential of this supplement combination as a therapeutic option for menopausal symptom management.

trial registrationClinicalTrials.gov NCT06328348.

Indexed as

CimicifugaGlycine maxIsoflavonesLignansMenopausePlant ExtractsDietary SupplementsDouble-Blind MethodEstradiolFemaleHot FlashesHumansMiddle AgedPostmenopauseEstradiolIsoflavonesLignansPlant ExtractsBlack CohoshMenopauseMenopause Rating ScaleSDG LignansSoy Isoflavones

Identifiers

PMID40131516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.